Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time
This article was originally published in The Pink Sheet Daily
Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.
You may also be interested in...
The British HTA NICE wants more clinical and cost-effectiveness data on Janssen’s Velcade in combination therapy before clearing it for battle with thalidomide for multiple myeloma.
IQWiG turned down both GSK/Valeant’s Trobalt and Novartis’ Rasilamlo for lack of evidence of added benefit, after manufacturers’ choice of comparator deviated from those selected by the G-BA.
The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.